Bruce A Sullenger

List of Publications by Year
in descending order

74 papers	3,718 citations	186265 28 h-index	133252 59 g-index
77 all docs	77 docs citations	77 times ranked	4065 citing authors

#	Article	IF	Citations
1	Aptamers as Therapeutics. Annual Review of Pharmacology and Toxicology, 2017, 57, 61-79.	9.4	383
2	Antidote-mediated control of an anticoagulant aptamer in vivo. Nature Biotechnology, 2004, 22, 1423-1428.	17.5	318
3	Emerging clinical applications of RNA. Nature, 2002, 418, 252-258.	27.8	304
4	From the RNA world to the clinic. Science, 2016, 352, 1417-1420.	12.6	225
5	Pre-existing antiâ€"polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. Journal of Allergy and Clinical Immunology, 2016, 137, 1610-1613.e7.	2.9	215
6	Group II Introns Designed to Insert into Therapeutically Relevant DNA Target Sites in Human Cells. Science, 2000, 289, 452-457.	12.6	203
7	Design of therapeutic biomaterials to control inflammation. Nature Reviews Materials, 2022, 7, 557-574.	48.7	187
8	Tagging ribozyme reaction sites to follow transâ€"splicing in mammalian cells. Nature Medicine, 1996, 2, 643-648.	30.7	125
9	Nucleic acid-binding polymers as anti-inflammatory agents. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14055-14060.	7.1	122
10	Development of universal antidotes to control aptamer activity. Nature Medicine, 2009, 15, 1224-1228.	30.7	108
11	Tunable cytotoxic aptamerâ€"drug conjugates for the treatment of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4761-4766.	7.1	108
12	Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nature Biotechnology, 1997, 15, 41-45.	17.5	95
13	Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12938-12943.	7.1	92
14	Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. Journal of NeuroInterventional Surgery, 2021, 13, 202-206.	3.3	75
15	Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. Nature Medicine, 1996, 2, 1386-1389.	30.7	71
16	Conformationally selective RNA aptamers allosterically modulate the Î²2-adrenoceptor. Nature Chemical Biology, 2016, 12, 709-716.	8.0	65
17	Scavenging nucleic acid debris to combat autoimmunity and infectious disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9728-9733.	7.1	60
18	Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers. Cell Chemical Biology, 2019, 26, 634-644.e3.	5.2	60

#	Article	IF	Citations
19	In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9. Molecular Therapy - Nucleic Acids, 2016, 5, e315.	5.1	52
20	Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis. Biomaterials, 2017, 120, 94-102.	11.4	52
21	Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. Nature Biotechnology, 2018, 36, 606-613.	17.5	52
22	Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. Molecular Therapy, 2019, 27, 1228-1241.	8.2	52
23	2â€²Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors. Nucleic Acid Therapeutics, 2016, 26, 173-182.	3.6	45
24	Targeted Disruption of Î²-Arrestin 2-Mediated Signaling Pathways by Aptamer Chimeras Leads to Inhibition of Leukemic Cell Growth. PLoS ONE, 2014, 9, e93441.	2.5	43
25	Modulation of the Coagulation Cascade Using Aptamers. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2083-2091.	2.4	42
26	Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Molecular Therapy, 2018, 26, 1020-1031.	8.2	42
27	Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test. Science Advances, 2021, 7, .	10.3	42
28	DAMPs/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists. Biomaterials, 2022, 283, 121393.	11.4	34
29	Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. Nucleic Acid Therapeutics, 2016, 26, 1-9.	3.6	32
30	Potent Anticoagulant Aptamer Directed against Factor IXa Blocks Macromolecular Substrate Interaction. Journal of Biological Chemistry, 2012, 287, 12779-12786.	3.4	28
31	Translation and Clinical Development of Antithrombotic Aptamers. Nucleic Acid Therapeutics, 2016, 26, 147-155.	3.6	26
32	The Inhibition of Anti-DNA Binding to DNA by Nucleic Acid Binding Polymers. PLoS ONE, 2012, 7, e40862.	2.5	22
33	Rapid test to assess the escape of SARS-CoV-2 variants of concern. Science Advances, 2021, 7, eabl7682.	10.3	21
34	Nucleic Acid Scavenging Polymers Inhibit Extracellular DNA-Mediated Innate Immune Activation without Inhibiting Anti-Viral Responses. PLoS ONE, 2013, 8, e69413.	2.5	20
35	PEGâ€Like Brush Polymer Conjugate of RNA Aptamer That Shows Reversible Anticoagulant Activity and Minimal Immune Response. Advanced Materials, 2022, 34, e2107852.	21.0	19
36	Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State. Cell Chemical Biology, 2020, 27, 232-244.e7.	5.2	18

#	Article	IF	Citations
37	Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer. Molecular Therapy, 2021, 29, 1772-1781.	8.2	18
38	Colocalizing ribozymes with substrate rnas to increase their efficacy as gene inhibitors. Applied Biochemistry and Biotechnology, 1995, 54, 57-61.	2.9	17
39	Probing the Interplay between the Two Steps of Group I Intron Splicing:Â Competition of Exogenous Guanosine with Ï‰Gâ€. Biochemistry, 1998, 37, 18056-18063.	2.5	17
40	The Nucleic Acid Scavenger Polyamidoamine Third-Generation Dendrimer Inhibits Fibroblast Activation and Granulation Tissue Contraction. Plastic and Reconstructive Surgery, 2014, 134, 420e-433e.	1.4	15
41	Probing the Coagulation Pathway with Aptamers Identifies Combinations that Synergistically Inhibit Blood Clot Formation. Chemistry and Biology, 2014, 21, 935-944.	6.0	13
42	An Aptamer for Broad Cancer Targeting and Therapy. Cancers, 2020, 12, 3217.	3.7	13
43	Therapeutic Aptamers: Evolving to Find their Clinical Niche. Current Medicinal Chemistry, 2020, 27, 4181-4193.	2.4	13
44	Histone Deacetylase 7 Inhibition in a Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury. Shock, 2020, 53, 344-351.	2.1	12
45	Targeted genetic repair: an emerging approach to genetic therapy. Journal of Clinical Investigation, 2003, 112, 310-311.	8.2	12
46	Enhancing cardiac reprogramming via synthetic RNA oligonucleotides. Molecular Therapy - Nucleic Acids, 2021, 23, 55-62.	5.1	11
47	Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects. Molecular Therapy - Nucleic Acids, 2021, 26, 1-10.	5.1	11
48	Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs. Molecular Therapy, 2017, 25, 1295-1305.	8.2	10
49	IL-10 and class 1 histone deacetylases act synergistically and independently on the secretion of proinflammatory mediators in alveolar macrophages. PLoS ONE, 2021, 16, e0245169.	2.5	10
50	Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. Anesthesiology, 2022, 137, 67-78.	2.5	8
51	Riboswitches â€” To Kill or Save the Messenger. New England Journal of Medicine, 2004, 351, 2759-2760.	27.0	7
52	Aptamers to Proteins. , 2006, , 131-166.		7
53	Immobilization of nucleic acid binding polymers as anti-inflammatory agent in autoimmunity. Journal of Controlled Release, 2015, 213, e136.	9.9	7
54	RNA-Mediated Reprogramming of Primary Adult Human Dermal Fibroblasts into c-kit⁺ Cardiac Progenitor Cells. Stem Cells and Development, 2015, 24, 2622-2633.	2.1	7

#	Article	IF	Citations
55	Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts. Biochemical and Biophysical Research Communications, 2016, 478, 1484-1490.	2.1	7
56	Toll-like receptor activation as a biomarker in traumatically injured patients. Journal of Surgical Research, 2018, 231, 270-277.	1.6	7
57	Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury. Journal of Visualized Experiments, 2018, , .	0.3	6
58	Targeting DAMPs with nucleic acid scavengers to treat lupus. Translational Research, 2022, 245, 30-40.	5.0	6
59	Aptamers Coming of Age at Twenty-Five. Nucleic Acid Therapeutics, 2016, 26, 119-119.	3.6	5
60	RGEN Editing of RNA and DNA: The Long and Winding Road from Catalytic RNAs to CRISPR to the Clinic. Cell, 2020, 181, 955-960.	28.9	5
61	Î²-Cyclodextrin-containing polymer treatment of cutaneous lupus and influenza improves outcomes. Molecular Therapy, 2022, 30, 845-854.	8.2	5
62	Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples. Cell Chemical Biology, 2022, 29, 215-225.e5.	5.2	5
63	Blocking Adhesion of Sickle Erythrocytes to Endothelial P-Selectin Using an RNA Aptamer.. Blood, 2007, 110, 147-147.	1.4	2
64	Key Pathogenic Factors in Coronavirus Disease 2019â€"Associated Coagulopathy and Acute Lung Injury Highlighted in a Patient With Copresentation of Acute Myelocytic Leukemia: A Case Report. A&A Practice, 2021, 15, e01432.	0.4	1
65	Blocking Complement-Mediated Hemolysis of PNH Erythrocytes by RNA Aptamers to C8 and C9.. Blood, 2004, 104, 2824-2824.	1.4	0
66	Blocking Complement-Mediated Hemolysis Using RNA Aptamers That Bind Complement Component C8.. Blood, 2005, 106, 186-186.	1.4	0
67	Blocking Adhesion of Sickle Erythrocytes to Endothelial Î±VÎ²3 Using RNA Aptamer.. Blood, 2006, 108, 688-688.	1.4	0
68	Effect of PAI-1 Specific RNA Aptamers On Cell Adhesion and Motility.. Blood, 2009, 114, 2135-2135.	1.4	0
69	Laboratory Assessment of Anti-Coagulant Properties of a Von Willebrand Factor Targeted Aptamer. Blood, 2014, 124, 4279-4279.	1.4	0
70	X-Ray Structure of an Anticoagulant RNA Aptamer Bound to Factor Xa. Structural Basis for Its Ability to Disrupt Interactions Between Xa and Va within Prothrombinase. Blood, 2014, 124, 4232-4232.	1.4	0
71	Cell-Free DNA Is Elevated after Acute Arterial Injury in Infants. Blood, 2016, 128, 5002-5002.	1.4	0
72	RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit. Blood, 2016, 128, 3823-3823.	1.4	0

#	Article	IF	Citations
73	Aptamer Mediated Inhibition of Protein S. Blood, 2016, 128, 4946-4946.	1.4	0
74	Blocking pro-invasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NASs).. Journal of Clinical Oncology, 2020, 38, e13096-e13096.	1.6	0